My name is Ross (Roshan) Chikarmane, PhD and I’m a biotech company builder, investor, and scientist.

During my time as a Healthcare Associate at RA Capital, a biotech-focused multi-stage investment fund based out of Boston, I:

• Led real-time valuation and investment recommendations for 100+ public and private companies in the metabolic, cardiology, liver, and kidney disease spaces, resulting in 2 exits (Alpine Immune Sciences acquired by Vertex Pharmaceuticals, Cymabay acquired by Gilead Sciences) and $100M's of invested capital.

• Spearheaded new company creation and charted development & financing roadmaps from discovery to approval, resulting in ~$20 million aggregate Seed/pre-Seed funding for 3 new company builds in the orphan enzyme replacement therapy (ERT) and genetic kidney disease spaces.

• Evaluated 30+ drug licensing opportunities sourced from big pharma, small/mid cap biotech, and ex-US biotechs for portfolio company pipeline expansion or new company builds.

I earned my PhD in Pharmacology from the Johns Hopkins School of Medicine, where I studied prostate cancer genomics and combinatorial drug discovery in the lab of Dr. Vasan Yegnasubramanian. At Johns Hopkins, I also the opportunity to accelerate research commercialization at Johns Hopkins Technology Ventures (JHTV) and facilitate academia-industry discourse by starting the Hopkins Biotech Podcast.

Contact me on LinkedIn, Twitter, or by email.